Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Stem Cells Transl Med ; 1(3): 221-9, 2012 Mar.
Article in English | MEDLINE | ID: mdl-23197781

ABSTRACT

Chronic wounds continue to be a major cause of morbidity for patients and an economic burden on the health care system. Novel therapeutic approaches to improved wound healing will need, however, to address cellular changes induced by a number of systemic comorbidities seen in chronic wound patients, such as diabetes, chronic renal failure, and arterial or venous insufficiency. These effects likely include impaired inflammatory cell migration, reduced growth factor production, and poor tissue remodeling. The multifunctional properties of bone marrow-derived mesenchymal stem cells (MSCs), including their ability to differentiate into various cell types and capacity to secrete factors important in accelerating healing of cutaneous wounds, have made MSCs a promising agent for tissue repair and regeneration. In this study we have used an in vitro scratch assay procedure incorporating labeled MSCs and fibroblasts derived from normal donors and chronic wound patients in order to characterize the induction of mobilization when these cells are mixed. A modified Boyden chamber assay was also used to examine the effect of soluble factors on fibroblast migration. These studies suggest that MSCs play a role in skin wound closure by affecting dermal fibroblast migration in a dose-dependent manner. Deficiencies were noted, however, in chronic wound patient fibroblasts and MSCs as compared with those derived from normal donors. These findings provide a foundation to develop therapies targeted specifically to the use of bone marrow-derived MSCs in wound healing and may provide insight into why some wounds do not heal.


Subject(s)
Cell Movement/physiology , Mesenchymal Stem Cells/cytology , Mesenchymal Stem Cells/physiology , Skin/injuries , Wound Healing/physiology , Wounds and Injuries/therapy , Adult , Bone Marrow Cells/cytology , Bone Marrow Cells/physiology , Chronic Disease , Coculture Techniques , Fibroblasts/cytology , Fibroblasts/physiology , Flow Cytometry , Humans , Skin/cytology , Skin/physiopathology , Wounds and Injuries/pathology
2.
Wound Repair Regen ; 15(6): 856-65, 2007.
Article in English | MEDLINE | ID: mdl-18028134

ABSTRACT

Bone marrow-derived cells have long been regarded to play a crucial role in the homeostasis of skin. We have previously described the clinical benefit of directly applying autologous bone marrow aspirate and cultured bone marrow cells to recalcitrant chronic skin wounds. The initial response to treatment appears to be vascular in nature with the formation of new blood vessels. The difficulty in consistently growing adequate numbers of cells for delivery to patients was, however, a limiting factor. Here, in a subsequent protocol, we describe an improved bone marrow culture system yielding a reliable growth of bone marrow cells and leading to a greater clinical response. Cells expressing markers of endothelial progenitors including CD133, CD146, and particularly CD14 are enhanced in these cultures. CD14-isolated cells produced colonies in endothelial cell assays and sprouting in matrigel assays. Angiogenic cytokines, including angiogenin, epithelial neutrophil-activating protein-78, growth-regulated oncogene, growth-regulated oncogene-alpha, Interleukin-8, CXC16, and monocyte chemoattractant protein-1, were found to be elevated in these cultures. Administration of improved culture cells to patients with chronic wounds present for >1 year lead to an enhanced clinical response.


Subject(s)
Bone Marrow Transplantation/methods , Wound Healing/physiology , Wounds and Injuries/therapy , Administration, Topical , Cells, Cultured , Chronic Disease , Cytokines/metabolism , Humans , Injections , Occlusive Dressings , Skin/pathology , Transplantation, Autologous , Treatment Outcome
3.
J Leukoc Biol ; 72(3): 580-9, 2002 Sep.
Article in English | MEDLINE | ID: mdl-12223527

ABSTRACT

Interleukin (IL)-13 regulates monocyte function and is a potent stimulator of 15-lipoxygenase expression. In different cell types, the functional IL-13 receptor complex can be comprised of variable protein components and has not been thoroughly examined in human monocytes. Here, we identify the receptor components and upstream signaling events initiated by IL-13 in primary human blood monocytes. The expression, phosphorylation and associated Jak kinases of the known, variable receptor components, IL-4R(alpha), IL-2Rgammac, IL-13R(alpha)1 and IL-13R(alpha)2, were examined. We determined that IL-4R(alpha) and IL13R(alpha)1 are phosphorylated upon exposure to IL-13. Although IL-2Rgammac is also expressed, it is not phosphorylated upon exposure to IL-13. Evaluation of the presence of IL-13R(alpha)2 failed to reveal significant mRNA or protein expression. Earlier, our laboratory showed that IL-13 induced the phosphorylation of Jak2 and Tyk2 in monocytes and that expression of both Jaks was essential for downstream signaling by IL-13. Here, we report that Jak2 is associated with IL-4R(alpha), and Tyk2 is associated with the IL-13R(alpha)1 component of the IL-13 receptor complex. Additionally, Stat proteins 1alpha, 3, 5A, 5B, and 6 are phosphorylated in response to IL-13. Further, the nuclear translocation and DNA binding of each of these Stats were induced by IL-13. These data represent the first complete report of the functional IL-13 receptor complex and early signaling events in human monocytes. This information is critical for understanding the IL-13 response of monocytes in inflammation.


Subject(s)
Interleukin-13/physiology , Milk Proteins , Monocytes/metabolism , Proto-Oncogene Proteins , Receptors, Interleukin/drug effects , Signal Transduction/physiology , Active Transport, Cell Nucleus , DNA/metabolism , DNA-Binding Proteins/metabolism , Humans , Inflammation/metabolism , Interferon-Stimulated Gene Factor 3 , Interleukin-13/pharmacology , Interleukin-13 Receptor alpha1 Subunit , Janus Kinase 2 , Macromolecular Substances , Monocytes/drug effects , Phosphorylation , Protein Processing, Post-Translational , Protein Subunits , Protein-Tyrosine Kinases/metabolism , Proteins/metabolism , RNA, Messenger/biosynthesis , Receptors, Interleukin/chemistry , Receptors, Interleukin/genetics , Receptors, Interleukin/physiology , Receptors, Interleukin-13 , Receptors, Interleukin-2/chemistry , Receptors, Interleukin-2/metabolism , Receptors, Interleukin-4/chemistry , Receptors, Interleukin-4/metabolism , Recombinant Fusion Proteins/pharmacology , STAT3 Transcription Factor , STAT5 Transcription Factor , STAT6 Transcription Factor , Signal Transduction/drug effects , TYK2 Kinase , Trans-Activators/metabolism , Transcription Factors/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...